Risk assessment of outpatient dermatology practice in the setting of the COVID-19 pandemic - 10/10/20
Funding sources: None. |
|
Disclosure: Dr Gerami has served as a consultant for Myriad Genomics, DermTech, Merck, and Castle Biosciences and has received honoraria for this. Dr Liszewski has no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
Vol 83 - N° 5
P. 1538-1539 - novembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.